Merck (MRK) Tops Q3 EPS by 40c, Beats on Revenue; Offers FY Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. VRTX
4. DOX
5. CRWD
6. CHKP
7. ON
8. HNGE
9. INSP
10. CVI

Go back to Merck (MRK) Tops Q3 EPS by 40c, Beats on Revenue; Offers FY Guidance

Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline

October 29, 2026 6:30 AM EDT

Sales Growth Reflects Continued Strength in Oncology and Animal Health, Plus Contributions From Other Products in Broader Portfolio, Including WINREVAIR

Financial Highlights

Total Worldwide Sales Were $18.1 Billion (5% Growth; 4% Growth ex-FX) KEYTRUDA/KEYTRUDA QLEX1 Sales Were $8.6 Billion (6% Growth; 6% Growth ex-FX); Includes KEYTRUDA QLEX Sales of $830 Million WINREVAIR Sales Were $694 Million (93% Growth; 94% Growth ex-FX) Animal Health Sales Were $1.7 Billion (4% Growth; 3% Growth ex-FX) GAAP EPS Was $2.04; Non-GAAP EPS Was $2.49; GAAP and Non-GAAP EPS Include a One-Time Charge of $0.12 per Share Related to a Global License Agreement... More